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1 |  INTRODUCTION
Chronic kidney disease (CKD) is a leading risk factor for 
cardiovascular and all-cause mortality. The 5-year mortality 
of end-stage renal disease (ESRD) hemodialysis patients ap-
proaches 50% (McGill et al., 2019), and most of these deaths 
are related to cardiovascular disease (CVD) (Felasa, 2012), 
making ESRD a catastrophic risk factor (Luft, 2000). Dietary 
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Abstract
Omega-3 (n-3) fatty acids have beneficial cardiovascular effects, perhaps also in 
chronic kidney disease (CKD) patients. A low omega-3 index is an independent car-
diovascular risk factor in end-stage renal disease (ESRD) dialysis patients. However, 
the plasma measurements invariably ignore circulating blood cells, including the 
preponderant erythrocytes (RBCs). We measured fatty acids (HPLC-MS lipidom-
ics) in all components of the circulating blood, since RBC n-3 fatty acid status has 
been linked to cardiovascular disease and mortality. We studied 15 healthy persons 
and 15 CKD patients undergoing regular hemodialysis treatments. While total fatty 
acid levels differed significantly in RBCs from healthy controls and CKD patients, 
the hemodialysis treatment had no effect on plasma or RBC fatty acid levels. No 
changes occurred in the percentage of eicosapentaenoic acid (C20:5 n-3, EPA) and 
docosahexaenoic acid (C22:6 n-3; DHA) (omega-3 quotient) in RBC membrane 
fatty acids. Nonetheless, hemodialysis treatments increased plasma levels of various 
total fatty acids, namely C12:0, C14:0, C16:0, C20:2 n-6, C20:4 n-6, and C22:6 n-3 
(DHA), while plasma levels of free fatty acids were unchanged. These data suggest 
that despite significant changes in fatty acids signatures between healthy persons and 
CKD patients, hemodialysis does not alter RBC n-3 fatty acid status, including the 
omega-3 quotient. The dialysis treatment per se does not appear to be responsible for 
a lower omega-3 index in CKD patients.
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omega-3 (n-3) fatty acid intake is associated with a reduced 
CVD risk (Harris, Kris-Etherton, & Harris, 2008; Huang, 
Frohlich, & Ignaszewski, 2011; InterAct Consortium et al., 
2011). Erythrocyte red-blood-cell (RBC) n-3 fatty acid status 
is related to cardiac arrhythmias, myocardial infarction, and 
sudden cardiac death (Bucher, Hengstler, Schindler, & Meier, 
2002).
The two most important n-3 polyunsaturated fatty acids 
(PUFA) are eicosapentaenoic acid (C20:5 n-3, EPA) and 
docosahexaenoic acid (C22:6 n-3, DHA). However, the im-
pact of the individual fatty acids for the predicting risk is 
not clearly elucidated. In recent randomized, double-blind, 
placebo-controlled trials, dietary n-3 fatty acid supple-
mentation (3–6  g daily) improved coronary atherosclerosis 
(Schacky, Angerer, Kothny, Theisen, & Mudra, 1999), but 
had (1 g daily) no cardiovascular benefit in initially healthy 
adults or in diabetic patients (ASCEND Study Collaborative 
Group et al., 2018; Manson et al., 2019). Two more recent 
large-scale trials showed that dietary EPA (C20:5 n-3) (4 g 
daily) is effective for prevention of major coronary events in 
hypercholesterolemic patients (Yokoyama et al., 2007) and 
reduces cardiovascular events in patients with established 
CVD, including in those with diabetes mellitus and other 
risk factors (Bhatt et al., 2018). Current evidence suggests 
that circulating n-3 PUFA is also associated with lower risk 
of cardiovascular events and mortality in ESRD patients un-
dergoing regular hemodialysis treatment (Chowdhury et al., 
2014; Khor et al., 2018).
Omega-3 PUFA diets affect the RBC membrane 
fatty acid composition (Popp-Snijders, Schouten, van 
Blitterswijk, & van der Veen, 1986). For example, a daily 
fish-oil concentrate supplement, providing 3  g of n-3 
PUFA, increases incorporation of C20:5 n-3 into RBCs. 
This effect occurs at the expense of C18:2 n-6 fatty acids, 
indicating a possible role for RBC fatty acid profiles, 
that is, signatures, involved in the cardiovascular effects 
(Cartwright, Pockley, Galloway, Greaves, & Preston, 
1985). The n-6 fatty acid, C18:2, and the n-3 fatty acids, 
C18:2, C20:5 (EPA), and C22:6 (DHA), collectively pro-
tect against coronary artery disease (Wijendran & Hayes, 
2004). Patients with low RBC n-3 and n-6 fatty acid val-
ues, namely C16:1 (palmitoleic acid) and C18:0 (stearic 
acid), have an increased risk of acute coronary syndromes 
(Shearer, Pottala, Spertus, & Harris, 2009). Furthermore, 
C20:5 n-3 (EPA) and C22:6 n-3 (DHA) improve en-
dothelial function, lower systemic blood pressure, and 
have favorable effects on platelet function (Wijendran & 
Hayes, 2004). A low omega-3 index (the percentage of 
EPA  +  DHA in red-blood-cell lipids) independently in-
creases cardiovascular disease risk and mortality (Kim, 
Lee, & An, 2018; Kleber, Delgado, Lorkowski, & Marz, 
2016a; Kleber, Delgado, Lorkowski, Marz, & Schacky, 
2016b; Schacky, 2015; Thuppal et al., 2017). RBC fatty 
acid status is similarly important in patients with CKD and 
ESRD (Khor et al., 2018; Kim et al., 2018). However, the 
impact of fatty acid measurements in the blood or RBC 
membranes for the prediction of CVD and mortality has 
not been previously elucidated. Whether or not the hemo-
dialysis treatment itself affects blood or RBC membrane 
fatty acids is unknown. Conceivably, the hemodialysis 
treatment per se has a counterproductive effect on cardio-
vascular risk. We tested the hypothesis that hemodialysis 
affects RBC omega-3 quotients and fatty acid signatures 
(Figure 1).
2 |  METHODS
The Charité University Medicine institutional review board 
on the use of humans in research approved the study, and 
written informed consent was obtained. The study was duly 
registered: ClinicalTrials.gov, Identifier: NCT03857984; 
F I G U R E  1  Schematic illustration of 
the hypothetic influence of hemodialysis 
associated with blood passing through the 
dialyzer, oxidative stress, uremia and red 
blood cell (RBC)–endothelial interactions 
affecting relative EPA + DHA content in 
RBC, that is, omega-3 quotient, which is the 
percentage of EPA + DHA in red cell fatty 
acid lipids
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institutional review board, EA2/113/08. Recruitment was 
primarily via person-to-person interview. Prior to partici-
pation in the study, 15 healthy volunteers (6 male and 9 
female) and 15 CKD patients (7 male and 8 female) un-
dergoing regular hemodialysis treatment signed informed 
consent forms which outlined the treatments to be taken 
and the possible risks involved (Table 1). We included 
patients who had a history of renal failure and requiring 
hemodialysis/hemofiltration, aged  ≥18  years, and were 
able to consent in writing. Exclusion criteria for healthy 
control group were age <18 years, chronic illness requir-
ing specific medications (such as corticosteroids, for in-
stance), pregnancy, inability to follow simple instructions, 
or debilitating medical conditions. No healthy control sub-
jects were taking medications. The patients included in the 
group CKD were diagnosed for the following conditions: 
diabetes mellitus (4 patients), hypertension (3 patients), 
membranous glomerulonephritis (2 patients), ADPKD (au-
tosomal-dominant polycystic kidney disease) (1 patient), 
other, or unknown (5 patients).
Venous blood was collected in each healthy subject by 
subcutaneous arm vein puncture in the sitting position. In the 
group of dialyzed patients (CKD group), all the blood samples 
were collected on the fistula arm right before beginning of the 
dialysis (starting of the HD, pre-HD) and at the end of the dial-
ysis (5–15 min before termination, post-HD). Patients under-
went thrice-weekly dialysis, which lasted from 3 hr 45 min to 
5 hr, based on high flux AK 200 dialyzers (Gambro GmbH). 
All samples were analyzed for RBC fatty acids status and 
plasma fatty acids. RBCs were separated from EDTA blood 
by centrifugation, and fatty acids in RBCs or plasma were de-
termined by high-performance liquid chromatography-mass 
spectrometry (HPLC-MS) described in Fischer et al., (2014); 
Gollasch, Dogan, Rothe, Gollasch, and Luft (2019).
We performed sample size calculation for a difference in 
means in omega-3 quotients. We found that our study would 
require a sample size of 9 (number of pairs) to achieve a 
power of 80% and a level of significance of 5% (two sided), 
for detecting a mean of the differences of 2.1 (Harris, Del 
Gobbo, and Tintle (2017)) between pairs, assuming the stan-
dard deviation of the differences to be 1.7 (Fischer et al., 
2014; Gollasch et al., 2019). A 2.1% increase in omega-3 
index is associated with a 15% risk reduction for fatal cor-
onary heart disease relative to the mean level (Harris et al., 
2017). Thus, in our sample size calculation, statistical signif-
icance and clinical relevance both were taken into account.
Descriptive statistics were calculated, and variables were 
examined for meeting assumptions of normal distribution 
without skewness and kurtosis. We used the Shapiro–Wilk 
test to determine whether the data were normally distributed. 
In order to determine statistical significance, two-tailed t 
test or Mann–Whitney test were used to compare values of 
CKD versus control groups. Homogeneity of variances was 
asserted using Levene's test. Paired t test or paired Wilcoxon 
test was used to compare pre-HD versus post-HD values. 
The .05 level of significance (p) was chosen. All data are 
presented as mean ± SD. All statistical analyses were per-
formed using SPSS Statistics software (IBM Corporation) 
or All-Therapy statistics beta (AICBT Ltd).
3 |  RESULTS
3.1 | Clinical characteristics
The clinical and demographic characteristics of the patients 
and control subjects (Table 1) show that age between ESRD 
patients and the healthy subjects was not different. The body 
mass indices between the two groups were also not different. 
The ESRD patients had diabetes mellitus, hypertension, mem-
branous glomerulonephritis, autosomal-dominant polycys-
tic kidney disease (ADPKD), and other or unknown disease, 
as underlying causes. Major cardiovascular complications 
T A B L E  1  Characteristics of hemodialysis (HD) patients and 
control subjects
HD patients 
(n = 15)
Controls 
(n = 15)
Statistical 
significance
Age (n) 50 ± 18 47 ± 12 p > .05
Sex
Male (n) 6 7
Female (n) 9 8
Body mass index  
(kg/m2)
24.8 ± 3.4 24.7 ± 4.6 p > .05
Race (n)
Caucasian  
= 14
Caucasian  
= 14
Black = 1 Asian = 1
Cause of end-stage 
renal disease
Diabetes (n) 4
Hypertension (n) 3
Membranous GN 
(n)
2
ADPKD (n) 1
Other or unknown 5
Complications
Cardiovascular (n) 2
Cerebrovascular (n) 1
PAD (n) 3
Note: Data are presented as mean ± SD or frequencies.
Abbreviations: GN, glomerulonephritis; n, number of patients; PAD, peripheral 
artery disease.
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T A B L E  2  Comparison of blood fatty acids between control subjects versus hemodialysis (HD) patients before hemodialysis (n = 15 each)
(A) Total fatty acids in erythrocytes (RBC)
Amount
µg/g Control (mean ± SD) HD (mean ± SD)
p value
t test
(#Mann–Whitney test)
C12:0 4.544 ± 1.847 6.033 ± 2.598 .089#
C14:0 19.704 ± 8.466 21.248 ± 17.289 .486#
C14:1 n−5 0.923 ± 0.772 0.661 ± 1.317 .033#
C16:0 147.795 ± 33.600 151.751 ± 46.741 .792
C16:1 n−7 12.089 ± 5.733 10.718 ± 8.042 .187#
C18:0 139.167 ± 40.465 147.867 ± 49.442 .602
C18:1 n−9 (cis) 189.604 ± 29.953 202.867 ± 75.846 .967#
C18:1n−9 (trans) 5.718 ± 1.744 7.199 ± 4.501 .250
C18:2 n−6 151.432 ± 21.535 126.833 ± 46.121 .072
C18:3 n−3 6.870 ± 2.754 6.097 ± 3.448 .305#
C18:3 n−6 4.127 ± 1.855 2.670 ± 1.847 .016#
C20:1 n−9 2.703 ± 0.632 3.307 ± 1.407 .145
C20:2 n−6 1.746 ± 0.308 1.762 ± 0.471 .935#
C20:3 n−6 11.726 ± 2.078 9.600 ± 3.360 .046
C20:4 n−6 144.244 ± 17.584 133.665 ± 33.127 .284
C20:5 n−3 19.538 ± 9.789 18.558 ± 24.782 .021#
C22:1 n−9 1.132 ± 0.372 1.971 ± 1.461 .026#
C22:2 n−6 0.260 ± 0.097 0.307 ± 0.162 .348
C22:5 n−3 15.802 ± 2.565 17.445 ± 7.140 .413
C22:5 n−6 3.624 ± 0.664 3.077 ± 1.002 .089
C22:6 n−3 76.838 ± 25.022 75.603 ± 35.053 .461#
C24:1 n−9 2.360 ± 1.149 4.799 ± 2.767 .002#
(B) Total fatty acids in plasma
Amount
µg/ml Control (mean ± SD) HD (mean ± SD)
p value
t test
(#Mann–Whitney test)
C12:0 13.22 ± 11.31 12.00 ± 10.17 .624#
C14:0 48.00 ± 33.46 43.91 ± 45.24 .161#
C14:1 n−5 3.28 ± 3.63 2.99 ± 5.11 .367#
C16:0 220.18 ± 59.31 190.31 ± 80.84 .081#
C16:1 n−7 21.68 ± 9.68 20.30 ± 15.16 .412#
C18:0 146.92 ± 34.71 137.83 ± 48.88 .305#
C18:1 n−9 (cis) 281.00 ± 88.78 281.24 ± 158.52 .595#
C18:1n−9 (trans) 7.46 ± 3.20 6.34 + 6.32 .061#
C18:2 n−6 214.23 ± 44.62 192.13 ± 110.50 .037#
C18:3 n−3 13.63 ± 8.09 11.68 ± 5.68 .595#
C18:3 n−6 10.42 ± 6.19 9.04 ± 4.42 .624#
C20:1 n−9 3.47 ± 1.17 3.86 ± 2.14 .935#
C20:2 n−6 2.22 ± 0.78 2.15 ± 1.13 .486#
C20:3 n−6 13.98 ± 4.18 9.36 ± 5.00 .003#
C20:4 n−6 104.63 ± 27.37 70.47 ± 31.09 .001#
(Continues)
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(B) Total fatty acids in plasma
Amount
µg/ml Control (mean ± SD) HD (mean ± SD)
p value
t test
(#Mann–Whitney test)
C20:5 n−3 24.39 ± 13.10 19.48 ± 27.18 .023#
C22:1 n−9 2.09 ± 0.61 2.06 ± 0.74 .927
C22:2 n−6 0.00 ± 0.00 0.00 ± 0.00 n/a
C22:5 n−3 5.80 ± 1.74 4.80 ± 1.49 .102
C22:5 n−6 1.80 ± 0.70 1.23 ± 0.68 .021#
C22:6 n−3 51.18 ± 16.55 41.73 ± 27.37 .050#
C24:1 n−9 2.22 ± 0.65 2.39 ± 0.68 .497
(C) Free fatty acids in plasma
Amount
µg/ml Control (mean ± SD) HD (mean ± SD)
p value
t test
(#Mann–Whitney test)
C12:0 1.203 ± 0,353 2.196 ± 1.419 .001#
C14:0 2.696 ± 1.054 4.160 ± 1.239 .005#
C14:1 n−5 0.205 ± 0.226 0.308 ± 0.153 .048#
C16:0 24.484 ± 4.204 29.251 ± 6.602 .038
C16:1 n−7 2.185 ± 2.329 4.622 ± 2.807 .017#
C18:0 16.525 ± 2.152 17.919 ± 3.449 .226
C18:1 n−9 (cis) 16.385 ± 9.252 28.061 ± 13.685 .015
C18:1n−9 (trans) n.d. n.d. —
C18:2 n−6 5.681 ± 3.703 15.252 ± 14.938 .043#
C18:3 n−3 0.842 ± 0.658 2.234 ± 3.117 .043#
C18:3 n−6 0.127 ± 0.092 0.455 ± 0.505 .014#
C20:0 0.660 ± 0.113 0.848 ± 0.201 .008
C20:1 n−9 0.670 ± 0.378 1.501 ± 0.884 .006
C20:2 n−6 0.323 ± 0.069 0.527 ± 0.295 .012#
C20:3 n−6 0.082 ± 0.481 0.214 ± 0.219 .094#
C20:4 n−3 0.010 ± 0.056 0.029 ± 0.049 .017#
C20:4 n−6 1.049 ± 0.450 1.146 ± 0.846 .715
C20:5 n−3 0.640 ± 0.057 0.826 ± 2.394 .830#
C22:0 0.053 ± 0.020 0.167 ± 0.149 <.001#
C22:1 n−9 0.066 ± 0.450 0.232 ± 0.337 .076#
C22:2 n−6 n.d. n.d. —
C22:5 n−3 0.127 ± 0.590 0.459 ± 0.898 .012#
C22:5 n−6 0.066 ± 0.020 0.118 ± 0.121 .280#
C22:6 n−3 0.345 + 0.213 1.271 ± 3.089 .756#
C24:1 n−9 0.072 ± 0.018 0.117 ± 0.067 .036
(D) Free fatty acids in erythrocytes
Amount
µg/g Control (mean ± SD) HD (mean ± SD)
p value
t test
(#Mann–Whitney test)
C12:0 0.035 ± 0.014 0.069 ± 0.054 <.001#
T A B L E  2  (Continued)
(Continues)
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including cardiovascular and cerebrovascular events, and pe-
ripheral artery disease are given. Subjects were Caucasians, 
with the exception of one Black and one Asian subject in each 
group.
3.2 | Fatty acid status comparing controls to 
ESRD patients
We first determined the RBC fatty acid status in healthy 
control subjects and compared the results with ESRD pa-
tients (Table 2). The data demonstrate decreased incor-
poration of total EPA (C20:5 n-3), C14:1 n-5, C18:3 n-6, 
C20:3 n-6, and C22:1 n-9 and increased incorporation of 
total C24:1 n-9 levels into RBCs of CKD patients com-
pared to control subject (Table 2A). Moreover, the patients 
showed also lower levels of total C18:3 n-6 and C20:3 n-6 
fatty acids in RBCs. These differences occurred at the ex-
pense of increased levels of total C22:1 n-9 and C24:1 n-9 
fatty acids, because total RBC fatty acids were unchanged 
(Table 3A). No changes occurred in the levels of total 
C12:0, C14:0, C14:1 n-5, C16:0, C16:1 n-7, C18:0, C18:1 
n-9, C18:2 n-6, C18:3 n-3, C20:1 n-9, C20:2 n-6, C20:4 
n-6, C22:2 n-6, C22:5 n-3, C22:5 n-6, and C22:6 n-3 fatty 
acids in RBCs. The results on total fatty acids in plasma of 
control subjects and CKD patients are summarized (Table 
2B). The data demonstrate decreased levels of total C18:2 
n-6, C20:3 n-6, C20:4 n-6, C20:5 n-3 (EPA), and C22:5 
n-6 in plasma of CKD patients compared to control sub-
ject. No differences were observed in the levels of total 
C12:0, C14:0, C14:1 n-5, C16:0, C16:1 n-7, C18:0, C18:1 
n-9, C18:3 n-3, C18:3 n-6, C20:1 n-9, C20:2 n-6, C22:1 
n-9, C22:2 n-6, C22:5 n-3, C22:6 n-3, and C24:1 n-9 fatty 
acids in plasma. The levels of most free fatty acids (C12:0–
C24:1 n-9) measured were increased in plasma of CKD pa-
tients compared to healthy controls (Table 2C). The same 
was true for free fatty acids in RBCs (Table 2D).
We next inspected the omega-3 quotients in control sub-
jects and ESRD patients (Table 3). Within RBC, the omega-3 
quotient of total fatty acids was not different (Table 3A). 
No changes occurred in the omega-3 quotient, that is, the 
percentage of total eicosapentaenoic acid (C20:5 n-3; EPA) 
and docosahexaenoic acid (C22:6 n-3; DHA) in RBC fatty 
acids in the RBC membrane. However, the omega-3 quotient 
(D) Free fatty acids in erythrocytes
Amount
µg/g Control (mean ± SD) HD (mean ± SD)
p value
t test
(#Mann–Whitney test)
C14:0 0.200 ± 0.096 0.393 ± 0.133 <.001#
C14:1 n−5 0.008 ± 0.010 0.019 ± 0.010 .002#
C16:0 1.797 ± 0.213 3.346 ± 0.425 <.001
C16:1 n−7 0.199 ± 0.210 0.460 ± 0.257 .003#
C18:0 4.951 ± 0.817 8.431 ± 1.380 <.001
C18:1 n−9 (cis) 1.065 ± 0.489 2.863 ± 1.262 <.001
C18:1n−9 (trans) 0.056 ± 0.043 0.109 ± 0.060 .002#
C18:2 n−6 0.388 ± 0.217 1.355 ± 1.414 <.001#
C18:3 n−3 0.082 ± 0.058 0.302 ± 0.384 <.001#
C18:3 n−6 0.012 ± 0.007 0.038 ± 0.048 .008#
C20:1 n−9 0.041 ± 0.033 0.084 ± 0.053 .003#
C20:2 n−6 0.018 ± 0.012 0.055 ± 0.046 <.001#
C20:3 n−6 0.015 ± 0.007 0.034 ± 0.025 <.001#
C20:4 n−6 0.221 ± 0.065 0.374 ± 0.206 .007#
C20:5 n−3 0.037 ± 0.019 0.168 ± 0.492 .367#
C22:1 n−9 0.007 ± 0.003 0.034 ± 0.046 <.001#
C22:2 n−6 0.001 ± 0.001 0.003 ± 0.003 <.001#
C22:5 n−3 0.413 ± 0.212 2.107 ± 3.741 <.001#
C22:5 n−6 0.201 ± 0.114 0.530 ± 0.624 .006#
C22:6 n−3 0.051 ± 0.025 0.222 ± 0.456 .002#
C24:1 n−9 0.361 ± 0.166 0.955 ± 0.508 <.001
Note: Bold indicates major fatty acids critical for the omega 3- quotient (Figure 1).
T A B L E  2  (Continued)
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of free fatty acids within RBC showed increased values for 
C20:5 n-3 (EPA) + C22:6 n-3 (DHA) and increased total free 
fatty acids in ESRD patients, compared to controls (Table 
3B). The omega-3 quotient of free fatty acids in erythrocytes 
of CKD patients did not differ from the quotient measured 
in control subjects, despite higher free C20:5 n-3 (EPA) plus 
C22:6 n-3 (DHA) levels and lower total levels of free fatty 
acids (C12:0–C24:1 n-9) in the RBCs of CKD patients.
3.3 | Effects of hemodialysis
We inspected the effects of hemodialysis treatment on 
blood fatty acids in the CKD patients before (pre-HD) 
hemodialysis and at cessation (post-HD) of hemodialy-
sis in the 15 ESRD patients (Table 4). The total fatty 
acids in RBCs were not significantly affected (except for 
C18:2, which showed a slight decrease after hemodialy-
sis) (Tables 4A). The total fatty acids in plasma showed 
a significant increase in C12:0, C14:0, C16:0, and C24:1 
or decrease in C18:0, C20:2, and C20:4 (Table 4B). The 
free fatty acids in plasma were not affected by the he-
modialysis treatment (Table 4C). Similarly, the free 
fatty acid concentrations within RBCs were not affected 
(Table 4D). Since both circulating total and free C18:3 
n-6, C20:3 n-6, C20:5 n-3 (EPA), C22:1 n-9, and C24:1 
n-9 fatty acids in plasma were not affected by hemodialy-
sis, the observed changes in total RBC C18:3 n-6, C20:3 
n-6, C20:3 n-6, C20:5 n-3 (EPA), C22:1 n-9, and C24:1 
n-9 levels in ESRD patients are unlikely caused by uptake 
into "exchangeable" or "reversibly bound" free fatty acid 
pools in the erythrocytes in response to individual hemo-
dialysis treatments.
We also inspected the effects of hemodialysis on omega-3 
quotients (Table 5). C20:5 n-3 (EPA)  +  C22:6 n-3 (DHA) 
values in RBCs have not increased (p = .053), while no ef-
fects were also observed on total fatty acids or [C20:5 n-3 
(EPA) + C22:6 n-3 (DHA)]/ total fatty acids in RBCs (Table 
5A). Similarly, no effects were observed on the sum of RBC 
free fatty acids or omega-3 quotient of free fatty acids in 
RBCs (Table 5B). Thus, no fatty acid-level variations were 
found in RBCs in response to hemodialysis. Furthermore, no 
changes occurred also in the RBC omega-3 quotient in re-
sponse to hemodialysis. Together, the findings indicate that 
ESRD is associated with an altered RBC fatty acid status, 
that is, individual signature, which has no effect on the eryth-
rocyte n-3 fatty acid quotient. Moreover, hemodialysis treat-
ment is insufficient to change the RBC fatty acid signature of 
ESRD patients.
Of note, hemodialysis affected the total levels of vari-
ous saturated and n-6 fatty acids in plasma, which increased 
during hemodialysis. These fatty acids included C12:0, 
C14:0, C16:0, C20:2 n-6, C20:4 n-6, and C24:1 n-9, which 
were detected as total fatty acids (Table 4B), but not in free 
state (Table 4C). In contrast, hemodialysis did not affect the 
levels of total C14:1 n-5, C16:1 n-7, C18:1 n-9, C18:2 n-6, 
C18:3 n-3, C18:3 n-6, C20:1 n-9, C20:3 n-6, C20:5 n-3, 
C22:1 n-9, C22:2 n-6, C22:5 n-3, C22:5 n-6, and C22:6 n-3 
fatty acids in plasma.
4 |  DISCUSSION
We evaluated blood fatty acids in normal controls and ESRD 
patients. Also, we studied the effects of the hemodialysis 
treatment, which could be deleterious. Unique is the fact that 
T A B L E  3  Omega-3 quotients in control subjects versus hemodialysis (HD) patients before hemodialysis (n = 15 each)
(A) Omega−3 quotient of RBC total fatty acids
Fatty acid
(µg/g)
Control
(Mean ± SD)
ESRD
(Mean ± SD)
t test, p value
(#Mann–Whitney test)
C20:5 n−3 (EPA) + C22:6 n−3 (DHA) 96.377 ± 28.078 94.161 ± 54.387 .233#
Total fatty acids in RBCs 961.952 ± 139.688 954.043 ± 234.962 .912
C20:5 n−3
(EPA) ± C22:6 n−3 (DHA)]/ total fatty acids in RBCs
0.100 ± 0.021 0.100 ± 0.056 .325#
(B) Omega−3 quotient of RBC free fatty acids
Fatty acid
(µg/g)
Control 
(Mean ± SD)
ESRD
(Mean ± SD)
t test, p value
(#Mann–Whitney test)
C20:5 n−3 (EPA) + C22:6 n−3
(DHA)
0.088 ± 0.031 0.389 ± 0.951 .011#
Total free fatty acids 10.16 ± 1.93 21.96 ± 9.30 <.001#
[C20:5 n−3
(EPA) + C22:6 n−3
(DHA)]/ Total free fatty acids
0.0087 ± 0.0027 0.0114 ± 0.0178 .202#
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T A B L E  4  Effects of hemodialysis treatment on blood fatty acids in the CKD patients before (pre-HD) hemodialysis and at cessation (post-
HD) of hemodialysis (n = 15 each)
(A) Total fatty acids in erythrocytes
Amount
µg/g Pre-HD (mean ± SD) Post-HD (mean ± SD)
p value
Paired t test
(#paired Wilcoxon test)
C12:0 6.033 ± 2.598 6.047 ± 3.472 .776#
C14:0 21.248 ± 17.289 20.794 ± 18.874 .910#
C14:1 n−5 0.661 ± 1.317 0.654 ± 1.409 .445#
C16:0 151.751 ± 46.741 142.066 ± 46.454 .456
C16:1 n−7 10.718 ± 8.042 8.763 ± 5.835 .061#
C18:0 147.867 ± 49.442 139.942 ± 53.184 .622
C18:1 n−9 (cis) 202.867 ± 75.846 190.543 ± 60.520 .233#
C18:1n−9 (trans) 7.199 ± 4.501 6.119 ± 4.864 .156#
C18:2 n−6 126.833 ± 46.121 111.659 ± 28.970 .045
C18:3 n−3 6.097 ± 3.448 6.178 ± 4.241 .820#
C18:3 n−6 2.670 ± 1.847 2.132 ± 1.039 .112#
C20:1 n−9 3.307 ± 1.407 3.006 ± 0.995 .405
C20:2 n−6 1.762 ± 0.471 1.698 ± 0.412 .609#
C20:3 n−6 9.600 ± 3.360 9.341 ± 3.521 .394#
C20:4 n−6 133.665 ± 33.127 137.584 ± 26.824 .487
C20:5 n−3 18.558 ± 24.782 19.364 ± 26.036 .112#
C22:1 n−9 1.971 ± 1.461 1.395 ± 0.758 .256#
C22:2 n−6 0.307 ± 0.162 0.303 ± 0.202 .955#
C22:5 n−3 17.445 ± 7.140 18.699 ± 7.148 .313
C22:5 n−6 3.077 ± 1.002 3.231 ± 0.937 .435
C22:6 n−3 75.603 ± 35.053 80.789 ± 37.475 .088#
C24:1 n−9 4.799 ± 2.767 4.680 ± 3.153 .890
(B) Total fatty acids in plasma
Amount
µg/ml Pre-HD (mean ± SD) Post-HD (mean ± SD)
p value
Paired t test
(#paired Wilcoxon test)
C12:0 12.00 ± 10.17 16.26 ± 15.70 .006#
C14:0 43.91 ± 45.24 55.09 ± 63.93 .048#
C14:1 n−5 2.99 ± 5.11 3.24 ± 5.25 .422#
C16:0 190.31 ± 80.84 212.30 ± 77.50 .016#
C16:1 n−7 20.30 ± 15.16 19.85 ± 12.12 .730#
C18:0 137.83 ± 48.88 151.93 ± 46.05 .026#
C18:1 n−9 (cis) 281.24 ± 158.52 316.19 ± 139.41 .096#
C18:1n−9 (trans) 6.34 ± 6.32 7.71 ± 9.91 .096#
C18:2 n−6 192.13 ± 110.50 218.67 ± 109.55 .158#
C18:3 n−3 11.68 ± 5.68 14.21 ± 11.07 .397#
C18:3 n−6 9.04 ± 4.42 10.98 ± 8.55 .397#
C20:1 n−9 3.86 ± 2.14 4.31 ± 1.85 .124#
C20:2 n−6 2.15 ± 1.13 2.32 ± 1.03 .041#
C20:3 n−6 9.36 ± 5.00 10.00 ± 5.15 .109#
(Continues)
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(B) Total fatty acids in plasma
Amount
µg/ml Pre-HD (mean ± SD) Post-HD (mean ± SD)
p value
Paired t test
(#paired Wilcoxon test)
C20:4 n−6 70.47 ± 31.09 77.44 ± 28.49 .035#
C20:5 n−3 19.48 ± 27.18 38.53 ± 96.14 .084
C22:1 n−9 2.06 ± 0.74 2.63 ± 1.35 .074
C22:2 n−6 0.00 ± 0.00 0.00 ± 0.00 n/a
C22:5 n−3 4.80 ± 1.49 5.66 ± 3.04 .140
C22:5 n−6 1.23 ± 0.68 1.41 ± 0.69 .397
C22:6 n−3 41.73 ± 27.37 50.37 ± 45.26 .433
C24:1 n−9 2.39 ± 0.68 2.79 ± 1.00 .022
(C) Free fatty acids in plasma
Amount
µg/ml Pre-HD (mean ± SD) Post-HD (mean ± SD)
p value
Paired t test
(#paired Wilcoxon Test)
C12:0 2.196 ± 1.419 2.398 ± 1.101 .937#
C14:0 4.160 ± 1.239 5.317 ± 2.810 .583#
C14:1 n−5 0.308 ± 0.153 0.574 ± 0.498 .187
C16:0 29.251 ± 6.602 30.510 ± 5.052 .994
C16:1 n−7 4.622 ± 2.807 5.093 ± 3.265 .974
C18:0 17.919 ± 3.449 18.521 ± 2.676 .960
C18:1 n−9 (cis) 28.061 ± 13.685 31.285 ± 10.839 .899
C18:1 n−9 (trans) n.d. n.d. —
C18:2 n−6 15.252 ± 14.938 14.577 ± 8.750 .814#
C18:3 n−3 2.234 ± 3.117 2.411 ± 2.138 .695#
C18:3 n−6 0.455 ± 0.505 0.393 ± 0.243 .754#
C20:0 0.848 ± 0.201 0.926 ± 0.173 .638
C20:1 n−9 1.501 ± 0.884 1.835 ± 0.956 .346
C20:2 n−6 0.527 ± 0.295 0.499 ± 0.198 .814#
C20:3 n−6 0.214 ± 0.219 0.194 ± 0.119 .875#
C20:4 n−3 0.029 ± 0.049 0.034 ± 0.046 .875#
C20:4 n−6 1.146 ± 0.846 1.257 ± 0.703 .875#
C20:5 n−3 0.826 ± 2.394 0.694 ± 1.840 .433#
C22:0 0.167 ± 0.149 0.172 ± 0.140 1.000#
C22:1 n−9 0.232 ± 0.337 0.269 ± 0.336 .209#
C22:2 n−6 n.d. n.d. —
C22:5 n−3 0.459 ± 0.898 0.423 ± 0.582 .875#
C22:5 n−6 0.118 ± 0.121 0.110 ± 0.770 .814#
C22:6 n−3 1.271 ± 3.089 1.155 ± 2.285 .347#
C24:1 n−9 0.117 ± 0.067 0.132 ± 0.090 .395
(D) Free fatty acid in erythrocytes
Amount
µg/g Pre-HD (mean ± SD) Post-HD (mean ± SD)
p value
Paired t test
(#paired Wilcoxon Test)
C12:0 0.082 ± 0.054 0.094 ± 0.068 .496#
(Continues)
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T A B L E  5  Effects of hemodialysis on omega-3 quotients (n = 15 each)
A. Omega-3 quotient of RBC total fatty acids in the CKD patients before (pre-HD) hemodialysis and at cessation (post-HD) of 
hemodialysis.
Fatty acid
(µg/g)
Pre-HD
(Mean ± SD)
Post-HD
(Mean ± SD)
Paired t test, p value
(#paired Wilcoxon Test)
C20:5 n−3 (EPA) + C22:6 n−3 (DHA) 94.161 ± 54.387 100.153 ± 58.031 .053#
Total fatty acids in RBCs 954.043 ± 234.962 914.992 ± 207.009 .390
[C20:5 n−3
(EPA) ± C22:6 n−3 (DHA)]/ total fatty acids 
in RBCs
0.100 ± 0.056 0.108 ± 0.049 .088#
B. Omega-3 quotient of plasma free fatty acids of the CKD patients before (pre-HD) hemodialysis (HI) and at cessation (post-HD) of 
hemodialysis (HII)
Fatty acid
(µg/ml)
Pre-HD
(Mean ± SD)
Post-HD
(Mean ± SD)
Paired t test, p value
(#paired Wilcoxon Test)
C20:5 n−3 (EPA) + C22:6 n−3
(DHA)
0.389 ± 0.951 0.288 ± 0.474 .211#
Total free fatty acids 21.96 ± 9.30 22.85 ± 4.86 .281#
[C20:5 n−3
(EPA) + C22:6 n−3
(DHA)]/ Total free fatty acids
0.0114 ± 0.0178 0.0115 ± 0.0167 .733#
(D) Free fatty acid in erythrocytes
Amount
µg/g Pre-HD (mean ± SD) Post-HD (mean ± SD)
p value
Paired t test
(#paired Wilcoxon Test)
C14:0 0.394 ± 0.133 0.490 ± 0.308 .281#
C14:1 n−5 0.019 ± 0.010 0.032 ± 0.031 .191#
C16:0 3.346 ± 0.425 3.519 ± 0.401 .196
C16:1 n−7 0.460 ± 0.257 0.552 ± 0.387 .357
C18:0 8.431 ± 1.380 8.716 ± 1.094 .484
C18:1 n−9 (cis) 2.863 ± 1.262 3.313 ± 1.274 .284
C18:1n−9 (trans) 0.109 ± 0.060 0.170 ± 0.178 .053#
C18:2 n−6 1.355 ± 1.414 1.279 ± 0.658 .609#
C18:3 n−3 0.302 ± 0.384 0.365 ± 0.352 .394#
C18:3 n−6 0.038 ± 0.048 0.033 ± 0.019 .609#
C20:1 n−9 0.084 ± 0.053 0.116 ± 0.097 .191#
C20:2 n−6 0.055 ± 0.064 0.062 ± 0.044 .211#
C20:3 n−6 0.034 ± 0.025 0.035 ± 0.015 .191#
C20:4 n−6 0.374 ± 0.206 0.395 ± 0.124 .125#
C20:5 n−3 0.168 ± 0.498 0.116 ± 0.268 .125#
C22:1 n−9 0.034 ± 0.046 0.049 ± 0.059 .281#
C22:2 n−6 0.003 ± 0.003 0.003 ± 0.002 .112#
C22:5 n−3 2.107 ± 3.741 1.750 ± 1.432 .394#
C22:5 n−6 0.530 ± 0.624 0.424 ± 0.199 .532#
C22:6 n−3 0.222 ± 0.456 0.172 ± 0.211 .256#
C24:1 n−9 0.955 ± 0.508 1.166 ± 0.579 .082
Note: Bold indicates major fatty acids critical for the omega 3- quotient (Figure 1).
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we included the erythron in the analysis, rather than merely 
plasma values. The issue is important since the RBC mass 
(>40% of the circulating blood) is important to n-3 homeo-
stasis and metabolism. Since ESRD patients die on dialysis 
within 5 years, the hypothesis that the treatment (in-and-of-
itself) could be injurious seems reasonable. Our study inves-
tigated effects on n-3 fatty acids, and we encompassed all of 
the components in the circulating blood.
To our knowledge, our study is the first study to assess 
the impact of single hemodialysis treatment on individual 
RBC fatty acids using large-scale lipidomics. Although we 
did not confirm our hypothesis that RBC fatty acids, includ-
ing the omega-3 quotient, vary during hemodialysis, we ob-
served significant differences in RBC fatty acid status, that 
is, specific fatty acid signatures, between ESRD patients and 
control subjects. However, the omega-3 quotient did not vary 
between CKD patients and healthy volunteers. Finally, he-
modialysis treatment did not induce increased mobilization 
of individual free fatty acids into plasma or erythrocytes, but 
caused greater rate of oxidation of total fatty acids, which 
accumulated in the circulating blood during hemodialysis.
4.1 | Omega-3 and omega-6 fatty acids
A low omega-3 index independently increases cardiovascular 
disease risk and mortality, perhaps also in CKD (Kim et al., 
(2018); Kleber et al., 2016b; Kleber et al., 2016a; Thuppal et 
al., 2017; Schacky, 2015). Consistent with a number of pre-
vious studies (for review see Khor et al. (2018)), we detected 
decreased RBC EPA (C20:5 n-3) levels in our CKD patients, 
compared to the control subjects. These changes were paral-
leled by decreased RBC C18:3 n-6 and C20:3 n-6 levels and 
decreased plasma levels of C18:2 n-6, C20:3 n-6, C20:4 n-6, 
C20:5 n-3, and C22:5 n-6, which is similar to previous find-
ings (Dasgupta, Kenny, & Ahmad, 1990; Dessi et al., 2014; 
Friedman, Moe, Perkins, Li, & Watkins, 2006; Friedman et 
al., 2006; Gomez Dumm, Giammona, Touceda, & Raimondi, 
2001; Pazda, Stepnowski, Sledzinski, Chmielewski, & Mika, 
2017; Peuchant et al., 1994; Sertoglu et al., 2014; Sikorska-
Wisniewska et al., 2017; Yerlikaya, Mehmetoglu, Kurban, & 
Tonbul, 2011), for review see Khor et al. (2018)). However, the 
omega-3 quotient did not vary between CKD patients and con-
trol subjects, which contrasts to numerous studies detecting a 
low omega-3 index in CKD patients (for review see Khor et al. 
(2018)). Interestingly, we did not detect changes in C18:3 n-3, 
which is inversely related to adiposity (Perng, Villamor, Mora-
Plazas, Marin, & Baylin, 2015). Together, the results indicate 
that there is an altered profile of n-3/ n-6 fatty acids in ESRD 
patients, which is confirmed by numerous clinical studies.
Dietary omega-3 fatty acids modulate the profile of eico-
sanoids in humans primarily via the cytochrome P450 (CYP)-
epoxygenase pathway, which could mediate cardioprotective 
and vasodilatory effects of n-3 fatty acids (Fischer et al., 2014). 
Recent results demonstrate that CYP enzymes efficiently con-
vert C20:5 n-3 (EPA) and C22:6 n-3 (DHA) to bioactive epoxy 
and hydroxy metabolites that could mediate some of the bene-
ficial cardiovascular effects of dietary n-3 fatty acids (Arnold 
et al., 2010). Thus, pharmacological interventions targeting the 
CYP-eicosanoid pathway could offer promising new options 
for cardiovascular disease risk and management. An alternative 
therapeutic approach is to focus on supplementation of individ-
ual fatty acids. As such, recent data show that dietary C20:5 
n-3 (EPA, 4 g daily, REDUCE-IT trial) is effective for preven-
tion of major coronary events in hypercholesterolemic patients 
(Yokoyama et al., 2007). Dietary C20:5 n-3 supplementation is 
also effective for prevention of cardiovascular events in patients 
with established cardiovascular disease or with diabetes and 
other risk factors (Bhatt et al., 2018). Our results demonstrate 
that RBC fatty acids, including the omega-3 quotient, do not 
vary during hemodialysis. The results are supported by stud-
ies, which did not use large-scale lipidomics but rather focused 
on individual fatty acids and used smaller number of patients 
(Friedman, Siddiqui, & Watkins, 2008; Peuchant et al., 1994; 
Peuchant, Salles, Vallot, Wone, & Jensen, 1988; Taccone-
Gallucci et al., 1989). Our results support the concept that the 
omega-3 quotient is strongly affected by diet, for example, 
C22:6 n-3/C20:5 n-3 fatty acid (DHA/EPA)-rich diet (Begum, 
Belury, Burgess, & Peck, 2004; Fischer et al., 2014; Saifullah 
et al., 2007), but not hemodialysis treatment itself. The baseline 
differences in RBC C20:5 n-3 (EPA), C18:3 n-6, and C20:3 n-6 
levels observed in CKD patients may contribute to increased 
cardiovascular risk in ESRD.
4.2 | Omega-9 fatty acids
High levels of omega-9 (n-9) monounsaturated fatty acids, 
C18:1 n-9 cis, C20:1 n-9, and C24:1 n-9 in RBCs have 
been associated with increased cardiovascular mortality in 
the Ludwigshafen Risk and Cardiovascular Health Study 
(Delgado et al., 2017). High levels of C16:0, C16:1 n-7, 
C18:1 n-9, and C18:3 n-3 in RBCs were also associated with 
increased risk of sudden cardiac death (Lemaitre et al., 2010, 
2009). Our study revealed elevated levels of RBC C22:1 n-9 
and C24:1 n-9 in CKD patients. These fatty acids could con-
tribute the increased cardiovascular risk in ESRD patients. 
Future studies are warranted to investigate biologic and prog-
nostic properties of n-9 fatty acids in cardiovascular disease 
progression in CKD and ESRD.
4.3 | Saturated fatty acids
Surprisingly, we did detect increases in total C12:0, C14:0, 
C16:0, and C18:0 plasma levels (besides C20:2 n-6 and 
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C20:4 n-6) in response to hemodialysis. Friedman et al. 
analyzed C18:0/C16:0 fatty acids and observed no change 
of C18:0, but a decrease of C16:0 fatty acid in response to 
a single hemodialysis (Friedman et al., 2008). The reasons 
for these changes and the discrepancies are unknown. The 
mechanism by which hemodialysis raises levels of individual 
saturated (C12:0, C14:0, C16:0 and C18:0) and n-6 (C20:2 
n-6 and C20:4 n-6) fatty acids in plasma is not known. Since 
long-chain PUFA cannot be synthesized endogenously in 
appreciable amounts, accelerated release into plasma could 
be a possible explanation. Consistently, the observed ac-
cumulation of fatty acids in plasma in did not occur at the 
expense of free fatty acids. In support of this notion, hemo-
dialysis treatment has been shown to upregulate lipoprotein 
lipase and phospholipase A2 activity, both of which produce 
fatty acids from triglycerides and phospholipids, respec-
tively (Friedman et al., 2008; Watkins, Li, Allen, Hoffmann, 
& Seifert, 2000). The more pronounced changes observed 
within the blood plasma, as compared with the RBC com-
partment, are not unexpected since plasma is considered 
more dynamic with respect to fatty acid flux (Friedman et 
al., 2008).
5 |  CONCLUSIONS
Our results suggest that hemodialysis treatment does not 
change the levels of RBC n-3 fatty acid status of ESRD pa-
tients in the systemic circulation. Our study revealed sig-
nificant differences in total and free RBC fatty acid status 
between ESRD patients and control subjects, although the 
omega-3 quotients did not vary between both groups. We also 
found that hemodialysis did not induce increased mobiliza-
tion of individual free fatty acids into plasma or erythrocytes, 
but caused greater rate of oxidation of total fatty acids, which 
accumulated (C12:0, C14:0, C16:0, C20:2 n-6 and C20:4 
n-6) in the circulating blood during hemodialysis treatment. 
Further studies are needed to elucidate the individual fatty 
acids altered in CKD for their cardiovascular risk predictions.
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